Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Treatment With Tacrolimus And Prednisolone Is Preferable To Intravenous Cyclophosphamide As The Initial Therapy For Children With Steroid-resistant Nephrotic Syndrome.

A. Gulati, A. Sinha, A. Gupta, M. Kanitkar, V. Sreenivas, J. Sharma, M. Mantan, I. Agarwal, A. Dinda, P. Hari, A. Bagga
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
There are limited data on the relative efficacy and safety of calcineurin inhibitors and alkylating agents for idiopathic steroid-resistant nephrotic syndrome in children. To clarify this, we compared tacrolimus and intravenous cyclophosphamide therapy in a multicenter, randomized, controlled trial of 131 consecutive pediatric patients with minimal change disease, focal segmental glomerulosclerosis, or mesangioproliferative glomerulonephritis, stratified for initial or late steroid resistance. Patients were randomized to receive tacrolimus for 12 months or 6-monthly infusions of intravenous cyclophosphamide with both arms receiving equal amounts of alternate-day prednisolone. The primary outcome of complete or partial remission at 6 months, based on spot urine protein to creatinine ratios, was significantly higher in children receiving tacrolimus compared to cyclophosphamide (hazard ratio 2.64). Complete remission was significantly higher with tacrolimus (52.4%) than with cyclophosphamide (14.8%). The secondary outcome of sustained remission or steroid-sensitive relapse of nephrotic syndrome at 12 months was significantly higher with tacrolimus than cyclophosphamide. Treatment withdrawal was higher with cyclophosphamide, chiefly due to systemic infections. Compared to cyclophosphamide, 3 patients required treatment with tacrolimus to achieve 1 additional remission. Thus, tacrolimus and prednisolone are effective, safe, and preferable to cyclophosphamide as the initial therapy for patients with steroid-resistant nephrotic syndrome.
This paper references
10.1681/ASN.2004070593
Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.
S. Troyanov (2005)
10.1007/s00467-003-1095-3
Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome
A. Bajpai (2003)
10.1007/BF00868243
Intravenous pulse cyclophosphamide — a new regime for steroid-resistant minimal change nephrotic syndrome
R. Elhence (2004)
[Efficacy and safety of cyclosporine A in treatment of refractory nephrotic syndrome in children: a systematic review of randomized controlled trials].
L. Chen (2009)
2813–2814
Melnikow J Chang D. Reporting number needed to treat Nuovo J (2012)
10.1001/JAMA.287.21.2813
Reporting number needed to treat and absolute risk reduction in randomized controlled trials.
J. Nuovo (2002)
10.3310/HTA11100
Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only.
A. Isaacs (2007)
10.1053/j.ajkd.2009.02.018
Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Xiayu Li (2009)
10.1046/J.1523-1755.1999.00778.X
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
D. Cattran (1999)
10.1007/BF00858129
A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome
C. Ponticelli (2004)
10.3310/HTA11210
The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review.
J. Colquitt (2007)
10.1053/j.ajkd.2008.11.033
Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
S. Choudhry (2009)
10.1007/s004670050574
Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis
W. Rennert (1999)
10.1007/s00467-010-1471-8
Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus
I. Roberti (2010)
10.1136/bmj.c332
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
K. Schulz (2010)
10.1038/SJ.KI.5002553
Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations.
D. Cattran (2007)
10.1007/s00467-009-1220-z
Experience with tacrolimus in children with steroid-resistant nephrotic syndrome
L. Butani (2009)
10.7326/0003-4819-152-11-201006010-00232
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
K. Schulz (2010)
10.1007/s004670050167
Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis
P. Tarshish (2009)
10.1002/14651858.CD003594.pub4
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Elisabeth M Hodson (2010)
10.1038/ki.2011.195
Clinical trial of focal segmental glomerulosclerosis in children and young adults.
D. Gipson (2011)
10.1046/j.1365-2796.2003.01207.x
Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure
K. Tryggvason (2003)
10.1053/j.ajkd.2009.04.029
Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
A. Levey (2009)
10.1093/NDT/GFM688
Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children.
S. Gulati (2008)
A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.
K. V. Lieberman (1996)
10.1681/ASN.2008030287
New equations to estimate GFR in children with CKD.
G. Schwartz (2009)
10.1007/s00467-008-0860-8
Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome
M. Mantan (2008)
10.1007/s00467-008-0794-1
Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie
C. Plank (2008)



This paper is referenced by
Comparison of Efficacy of Tacrolimus Versus Cyclosporine in Childhood Steroid-Resistant Nephrotic Syndrome.
Syed Sajid Hussain Shah (2016)
10.1007/s10157-017-1484-8
Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies
X. Jiang (2017)
10.1053/j.ajkd.2013.12.002
Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children.
S. Samuel (2014)
10.1080/00498254.2019.1669844
Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule
X. Chen (2019)
10.1007/s40746-016-0044-x
Nephrotic Syndrome: Updates and Approaches to Treatment
M. Rheault (2016)
10.1038/ki.2012.272
A new 'tac' for childhood nephrotic syndrome.
B. Becknell (2012)
10.1016/j.kint.2017.03.042
Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease.
H. Looker (2017)
10.3892/etm.2019.7446
Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models
Dongdong Wang (2019)
10.1007/s12519-015-0062-y
Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula
E. Yang (2015)
10.2147/IJNRD.S126844
Optimal management of primary focal segmental glomerulosclerosis in adults
S. Beaudreuil (2017)
10.1007/978-3-319-97220-6_8
Focal and Segmental Glomerulosclerosis (FSGS)
S. Nguyen (2019)
10.1007/s13312-016-0955-4
Discussion: The heart of the paper
A. Bagga (2016)
10.1186/s12916-016-0673-8
Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis
J. Singh (2016)
10.2215/CJN.06260614
Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.
A. Trautmann (2015)
10.1542/peds.2015-0486
Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome
Biswanath Basu (2015)
10.1371/journal.pone.0137049
Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease
Jian-Si Li (2015)
10.4103/0971-4065.107197
Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome
A. Sinha (2013)
10.1111/bcp.14174
Off‐label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics
Guo-xiang Hao (2019)
Efficacy and safety of tacrolimus in treating pediatric refractory nephrotic syndrome: a meta-analysis
D. Wang (2018)
10.1681/ASN.2016030342
Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome.
Xiayu Li (2017)
10.1016/j.krcp.2013.06.004
Primary glomerulonephritis: A review of important recent discoveries
J. Floege (2013)
10.4103/ijn.IJN_80_17
Adrenocortical Suppression in Children with Nephrotic Syndrome Treated with Low-Dose Alternate Day Corticosteroids
M. Mantan (2018)
10.1155/2016/3053706
Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children
K. Han (2016)
10.1097/FTD.0000000000000285
Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?
M. Medeiros (2016)
10.1111/apa.14409
National survey found that managing childhood nephrotic syndrome in Nigeria varied widely and did not comply with the best evidence
C. Esezobor (2018)
10.1136/jim-2016-000163
Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis
H. Fu (2016)
10.1007/s00467-016-3455-9
How randomised trials have improved the care of children with kidney disease
E. Hodson (2016)
10.1093/ckj/sfw028
Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis
Gema Fernández-Juárez (2016)
10.1007/s40124-014-0066-4
Nephrotic Syndrome: State of the Art
A. Sinha (2014)
10.1007/s00467-020-04476-9
Current understandings in treating children with steroid-resistant nephrotic syndrome
Jiwon M Lee (2020)
10.1038/nrneph.2012.289
Rituximab therapy in nephrotic syndrome: implications for patients' management
A. Sinha (2013)
Therapeutic variability in adultminimal change disease and focal segmental glomerulosclerosis
Gema Fernández-Juárez (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar